NPPA NOTIFICATION
In compliance with Order S.O. 5690(E) dated 17th October 2026 issued by the National Pharmaceutical Pricing Authority (NPPA), Department of Pharmaceuticals, Government of India, under Paragraph 19 of the Drugs (Prices Control) Order, 2013, the trade margin on specified non-scheduled anti-cancer medicines has been capped at 30%.
Accordingly, RPG LIFE SCIENCES LTD. has reduced the MRP of the following products. The revised MRPs will be effective from 9th November 2026.
| Sl. No. | Brand Name | Drug | Strength & Dosage Form | Pack Size | Current MRP (incl. of GST) (₹) |
Revised MRP (incl. of GST) (₹) Effective from 9th November 2026 |
|---|---|---|---|---|---|---|
| 1 | Abitate 250 mg Tablet | Abiraterone acetate | 250mg (Tablet) | 120 Nos | 25,883.24 | 5,261.00 |
| 2 | Abitate 500mg | Abiraterone acetate | 500mg (Tablet) | 60 Nos | 25,500.00 | 5,249.00 |
| 3 | Abitate U250mg | Abiraterone acetate | 250mg (Tablet) | 120 Nos | 37,417.36 | 6,278.00 |
| 4 | Abitate U500mg | Abiraterone acetate | 500mg (Tablet) | 60 Nos | 25,500.00 | 5,246.00 |
| 5 | ACALBRIGHT 100mg | Acalabrutinib | 100mg (Capsule) | 30 Nos | 17,999.00 | 7,962.00 |
| 6 | ANAROZOLE | Anastrozole | 1mg (Tablet) | 10 Nos | 695.76 | 73.00 |
| 7 | ARPRIDE 150mg | Olaparib | 150mg (Tablet) | 60 Nos | 19,500.00 | 11,999.00 |
| 8 | AZAPLAST 100MG INJ | Azacitidine | 100mg (Injection) | 1 Vial | 5,088.14 | 1,279.00 |
| 9 | Debrumab 60 mg | Denosumab | 60mg (Injection) | 1 mlpfs | 22,031.25 | 5,941.00 |
| 10 | Denbri | Denosumab | 60mg (Injection) | 1 mlpfs | 29,312.60 | 7,239.00 |
| 11 | Denosurask 60 mg | Denosumab | 60mg (Injection) | 1 mlpfs | 29,315.62 | 7,568.00 |
| 12 | Enzita | Enzalutamide | 40mg (Capsule) | 28 Nos | 6,578.20 | 2,232.00 |
| 13 | ENUTA 160MG 7's | Enzalutamide | 160mg (Capsule) | 7 Nos | 6,578.20 | 3,725.00 |
| 14 | EnzaMate 160mg | Enzalutamide | 160mg (Tablet) | 7 Nos | 6,578.20 | 3,134.00 |
| 15 | Enzamate 40mg | Enzalutamide | 40mg (Tablet) | 7 Nos | 6,578.20 | 2,212.00 |
| 16 | Enubin 50mg Inj 1's | Epirubicin | 50mg (Injection) | 1 Vial | 960.63 | 629.00 |
| 17 | Fulbreca 1's | Fulvestrant | 50mg (Injection) | 5ml Vial | 26,072.16 | 5,493.00 |
| 18 | Ivzumab 100mg | Bevacizumab | 100mg (Injection) | 1 Vial | 26,621.75 | 4,493.00 |
| 19 | Ivzumab 400mg | Bevacizumab | 400mg (Injection) | 1 Vial | 69,852.12 | 13,512.00 |
| 20 | Palbopro | Palbociclib | 125mg (Capsule) | 21 Nos | 40,421.33 | 2,720.00 |
| 21 | Peg Frasim | Pegfilgrastim | 6mg (Injection) | 1 Vial | 6,660.85 | 1,807.00 |
| 22 | PEMEXAR 100MG | Pemetrexed | 100mg (Injection) | 1 Vial | 1,892.98 | 468.00 |
| 23 | PEMEXAR 500MG | Pemetrexed | 500mg (Injection) | 1 Vial | 7,050.56 | 1,219.00 |
Ashok Nair
Managing Director, RPG Life Sciences Ltd.
Date: 24/10/2026
Place: Mumbai